Total Funding
87
95
Total FundingPost-IPO Secondary raised
Growth Score
-5 pts
Heat Score
28 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
176
Nuvalent is a biopharmaceutical company that develops targeted therapies for cancer by designing small-molecule medicines.
- James Porter: CEOPast Role: Infinity Pharmaceuticals, VP of Product Development
- Georg Meyer: Chief International OfficerPast Role: Blueprint Medicines, Senior Vice President
About the Company
Nuvalent is a biopharmaceutical company that develops targeted therapies for cancer by designing small-molecule medicines that address treatment resistance and improve selectivity against validated kinase targets. The company applies structure-based drug design and collaborates with clinical researchers to create therapies for patients whose
cancers are driven by specific genetic alterations. Its pipeline includes investigational treatments for ROS1-positive, ALK-positive, and HER2-altered cancers, with programs spanning multiple stages of clinical development. Nuvalent also conducts clinical trials and research activities focused on expanding treatment options for patients with solid tumors and other oncology indications.
